Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics

Journal of the American Academy of Dermatology

Volumn 57, Issue 2, 2007, Pages 269-275

  Papoutsaki, Marina ^a   Chimenti, Maria Sole ^b   Costanzo, Antonio ^a   Talamonti, Marina ^a   Zangrilli, Arianna ^a   Giunta, Alessandro ^a   Bianchi, Luca ^a   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LIVER FUNCTION TEST; LUPUS LIKE SYNDROME; LYMPHOMA; MALE; MULTIPLE SCLEROSIS; MYCOSIS; OPEN STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; QUESTIONNAIRE; RASH; REFRACTORY PERIOD; SCORING SYSTEM; SIDE EFFECT; TUBERCULOSIS; VERTIGO;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447293977     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.12.003     Document Type: Article

References (27)

1. Prinz J. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 17 (2003) 257-270
2. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 26 (2001) 314-320
3. Lebwohl M. Psoriasis. Lancet 361 (2003) 1197-1204
4. Schon M.P., and Boehncke W.H. Psoriasis. N Engl J Med 352 (2005) 1899-1912
5. Gladman D.D., and Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 9 (2000) 1511-1522
6. Tristani-Firouzi P., and Krueger G.G. Efficacy and safety of treatment modalities for psoriasis. Cutis 61 (1998) 11-21
7. Ashcroft D.M., Li Wan Po A., and Griffiths C.E. Therapeutic strategies for psoriasis. J Clin Pharm Ther 25 (2000) 1-10
8. Sterry W., Barker J., Boehncke W.H., Bos J.D., Chimenti S., Christophers E., et al. Biologicals in psoriasis consensus. Br J Dermatol 151 Suppl 69 (2004) 3-17
9. Salfeld J., Kaymakcalan Z., Tracey D., Roberts A., and Kamen R. Generation of fully human anti-TNF antibody D2E7. [abstract]. Arthritis Rheum 41 Suppl (1998) S57
10. Langley R., Leonardi C., Toth D., and Chen D.M. Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 52 Suppl (2005) P8
11. Ritchie D.M., Boyle J.A., McInnes J.M., Jasani M.K., Talakos T.G., Grieveson P., et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 37 (1968) 393-406
12. Fries J.F., Spitz P., Kraines R.G., and Holman H.R. Measurement of patient outcome in arthritis. Arthritis Rheum 23 (1980) 137-145
13. Finlay A.Y., and Khan G.K. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 19 (1994) 210-216
14. Lewis V., and Finlay A.Y. Ten years experience of the Dermatology Life Quality Index (DLQI D). J Investig Dermatol Symp Proc 9 (2004) 169-180
15. Finlay A.Y., and Kelly S.E. Psoriasis - an index of disability. Clin Exp Dermatol 12 (1987) 8-11
16. Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 4 (2005) 637-641
17. Chaudari U., Romano P., Mulcahy P., Dooley L.T., Barker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001) 1842-1847
18. Reich K., O'Nestle F., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate to severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
19. Mease P.J., Goffe B., Metz J., VanderStoep A., Fink B., and Burge D.J. Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-389
20. Leonardi C., Powers J., Matheson R., Goffe B.S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
21. Bianchi L., Giunta A., Papoutsaki M., Costanzo A., and Chimenti S. Efficacy and safety of long-term infliximab therapy in moderate to severe psoriasis and psoriatic arthritis. G Ital Dermatol Venereol 141 (2006) 73-78
22. Sharp J.T., Young D.Y., Bluhm G.B., Brook A., Brower A.C., Corbett M., et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?. Arthritis Rheum 28 (1985) 1326-1335
23. Mease P., Gladman D., Ritchlin C., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Artthitis Rheum 52 (2005) 3279-3289
24. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606 Epub 2006 Aug 10
25. Sladden M.J., Mortimer N.J., and Hutchinson P.E. Extensive plaque psoriasis successfully treated with adalimumab (Humira®). Br J Dermatol 152 (2005) 1062-1094
26. Chew A.L., Bennett A., Smith C.H., Barker J., and Kirkham B. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 151 (2004) 492-496
27. Tobin A.M., and Kirbi B. Successful treatment of recalcitrant acrodermatitis continua of Hallopeau with adalimumab and acitretin. Br J Dermatol 153 (2005) 440-446